Tirzepatide and Testosterone in Men Over 45
A man in his fifties carrying forty extra pounds, with a low testosterone result and every symptom to match, is the commonest patient in men's health telemedicine. The category's standard answer is testosterone. The evidence increasingly says that, for this specific man, the standard answer treats the number and misses the cause — and that tirzepatide may do both.
This page is about the sequence. The men's TRT page covers testosterone therapy itself.
Why obesity lowers testosterone
Fat tissue makes aromatase, the enzyme that converts testosterone to estradiol. More fat, more conversion, less testosterone — and the estradiol produced feeds back on the pituitary and tells it to make less LH, the signal that drives testosterone production in the first place. Insulin resistance and the inflammation that accompanies visceral fat suppress the signal further. Obstructive sleep apnea, common in this picture, suppresses it again.
The result is a specific kind of low testosterone: secondary, in the terms the primary vs secondary page sets out. The testes are fine. The signal has been turned down by the metabolic state. Clinicians increasingly call it metabolic hypogonadism, and the name is the point: it is a consequence of the metabolism, and it moves when the metabolism moves.
What weight loss does to it
This has been known for years from bariatric surgery: men who lose substantial weight after surgery see their testosterone rise, often into the normal range, without any hormone being prescribed. The question was whether medication-driven weight loss did the same.
It does. An 18-month observational study of 110 men with obesity on semaglutide, tirzepatide or dulaglutide, presented at ENDO 2025, found the share of men with normal total and free testosterone rose from 53% to 77% alongside roughly 10% weight loss.
More striking was a small randomized trial presented at the same meeting: 83 men with metabolic hypogonadism — obese, insulin-resistant, low testosterone, erectile difficulty — assigned to tirzepatide plus lifestyle, transdermal testosterone plus lifestyle, or lifestyle alone, for two months. The tirzepatide group had larger rises in total and free testosterone than the group actually taking testosterone, with erectile-function improvement similar to the testosterone group and far greater improvement in weight, waist and fat mass.
Two months and 83 men is a small, short trial and should be described as such. But its direction is consistent with everything else, and it answers the question this page is about.
What it changes about the order
For a man whose low testosterone is metabolic — obese, insulin-resistant, LH low or normal, no testicular cause — the honest first-line treatment is the one that addresses the metabolism. That may be tirzepatide. It may be semaglutide. It is not, in the first instance, testosterone, for three reasons.
Testosterone therapy treats the number and leaves the cause: the weight, the insulin resistance, the sleep apnea and the cardiovascular risk that travel with them remain. It switches off the man's own production, which is reversible but slow — see the fertility page. And it forecloses the diagnostic question: once a man is on testosterone, nobody ever finds out whether his own system would have recovered.
So the sequence at ACT 2 for this patient is: measure — testosterone, LH, FSH, SHBG, estradiol, the metabolic panel — treat the metabolism, and re-measure testosterone once weight has come down. Many men will not need a hormone at all. Some will, because the metabolic picture was only part of the story, and for them enclomiphene or replacement is the second step, on a cleaner baseline.
Where it does not apply
A man with primary hypogonadism — high LH, testes that cannot respond — will not recover testosterone by losing weight, though he may still benefit from tirzepatide for other reasons. A lean man with low testosterone has a different problem with a different workup. And a man whose symptoms are severe and whose weight will take a year to move may reasonably be offered both at once, with the plan to reassess the hormone once the weight has changed. That is a clinical judgement, made on the numbers.
We do not adjust or combine these medications on a formula, and this page does not describe one.
Frequently asked questions
In men with obesity and low testosterone, yes — through weight loss and improved insulin sensitivity. A 2025 trial found larger testosterone rises on tirzepatide than on testosterone therapy itself over two months.
If the low testosterone is metabolic — driven by weight and insulin resistance — treating the metabolism first is the honest sequence. Testosterone therapy treats the number and leaves the cause.
In the observational data, around 10% of body weight moved a substantial share of men back into the normal range. Individual response varies.
If the weight returns, the testosterone typically falls again. The hormone tracks the metabolic state.
Sometimes, on clinical judgement, with a plan to reassess. It is not a default, and it is not something to arrange yourself.
Yes, through the same mechanism. The observational data included semaglutide; the head-to-head trial used tirzepatide.
Where this fits in your plan
A baseline panel with LH, FSH, SHBG and free testosterone — not testosterone alone — tells us which kind of low testosterone you have. The Tirzepatide Injection page covers the medication; the low testosterone page covers the condition.
We measure first. Then we act.
References
- Portillo Canales S et al. Anti-obesity medications and testosterone normalization in men with obesity or type 2 diabetes. ENDO 2025, San Francisco.
- Tirzepatide versus testosterone therapy in men with metabolic hypogonadism: a randomized comparison. ENDO 2025.
- Corona G et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology 2013;168:829–843.
- Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. JCEM 2017;102:1067–1075.
- Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM 2018;103:1715–1744.
- Back toTirzepatide Injection
- Primary vs secondary low testosteroneTwo numbers on your panel — LH and FSH — say whether low testosterone starts in the testes or in the brain. That decides whether enclomiphene can work at all.Read
- Testosterone therapy for menMonitored testosterone replacement for men with diagnosed low testosterone.Read
- Tirzepatide for sleep apneaZepbound is the first medication approved for obstructive sleep apnea. What SURMOUNT-OSA found, who it applies to, and why a sleep study still comes first.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.